JNJ
EquityJohnson & Johnson
Health Care · Drug Manufacturers - General
$244.21
+244.21 (+0.00%)
Open
N/A
Day Range
$243.18 - $246.30
52W Range
$141.50 - $251.71
Volume
943K
Price History
Key Statistics
Market Cap
N/A
P/E Ratio
N/A
EPS
N/A
Dividend Yield
N/A
P/B Ratio
N/A
Payout Ratio
N/A
ROE
N/A
Debt/Equity
N/A
Latest News
Johnson And Johnson Balances Nipocalimab Progress With Bayer Legal Challenge
Retire Comfortably With These Dividend Growth Stocks
Johnson & Johnson therapy nipocalimab granted U.S. FDA Fast Track designation in systemic lupus erythematosus (SLE)
Zacks Industry Outlook Highlights Eli Lilly, Johnson & Johnson, Sanofi and Bayer
J&J’s blockbuster Spravato is setting the stage for managing psychedelics’ risks
Fair Value Estimate
DDM Value
$107.45
Growth: 4.9% | Req. return: 10%
Peers in Health Care
| Symbol | Name | Price | Mkt Cap | Div Yield | Change |
|---|---|---|---|---|---|
| ABBV | AbbVie Inc. | $233.86 | N/A | 2.84% | +0.00% |
| ACB | Aurora Cannabis Inc. | $3.71 | N/A | - | +0.00% |
| AKBA | Akebia Therapeutics, Inc. | $1.26 | N/A | - | +0.00% |
| ABCL | AbCellera Biologics Inc. | $3.74 | N/A | - | +0.00% |
| ACAD | ACADIA Pharmaceuticals Inc. | $22.81 | N/A | - | +0.00% |
| 001540.KQ | AHN-GOOK PHA | $7,870.00 | N/A | 5.59% | +0.00% |
| A | Agilent Technologies, Inc. | $116.88 | N/A | 0.85% | +0.00% |
| ABT | Abbott Laboratories | $114.12 | N/A | 2.10% | +0.00% |
About Johnson & Johnson
Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of a range of products in the healthcare field worldwide. It operates in two segments, Innovative Medicine and MedTech. The Innovative Medicine segment offers products for various therapeutic areas, such as oncology, immunology, neuroscience, pulmonary hypertension, infectious diseases, and cardiovascular and metabolism distributed through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use. The MedTech segment provides a portfolio of products used in the surgery, orthopedic, cardiovascular, and vision fields distributed through wholesalers, hospitals and retailers, and used in the professional fields by physicians, nurses, hospitals, eye care professionals and clinics. This segment also offers products and enabling technologies that support joint reconstruction, trauma, spine, sports related injuries, and others, as well as open, laparoscopic, and robotic surgical procedures; instrumentation, energy devices, stapling systems, wound closure, biosurgery products, and digital and robotic technologies; breast aesthetics and reconstruction; contact lenses under the ACUVUE brand; intraocular lenses for cataract surgery, and other products used in cataract and refractive procedures under the TECNIS brand. The company was founded in 1886 and is based in New Brunswick, New Jersey.
www.jnj.com →Dividend Safety
Assessment based on payout ratio, debt levels, profit margins, and dividend growth track record.
Safe
Based on 4 fundamental factors
Analysis Tools
Share
Dividend History
Dividend Safety
Assessment based on payout ratio, debt levels, profit margins, and dividend growth track record.
Safe
Based on 4 fundamental factors
Dividend Growth
1Y CAGR
+4.7%
3Y CAGR
+4.9%
5Y CAGR
N/A
10Y CAGR
N/A
5-Year Dividend Projection
| Year | Conservative | Base | Optimistic |
|---|
Based on historical CAGR. Not a guarantee of future dividends.
View Full Projection →Loading financial data...
Revenue & Earnings
No financial statement data available for JNJ.